CSL LTD SPON.ADR 2 (CSJA F) stock market data APIs
€65.0981
0(0%)
as of July 11, 2025
Try our APIs with
free plan!
CSL LTD SPON.ADR 2 Financial Data Overview
Price chart is built with
Anychart
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Prev. Close
65.0981
Open
65.0981
High
65.0981
Low
65.0981
52 wk Range
62-93.5173
Market Cap
65 773 M
P/E Ratio
28.2328
Shares Outstanding
968 M
Revenue
15 230 M
Dividends (Yield)
0.0187
Beta
0.351
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSL LTD SPON.ADR 2 data using free add-ons & libraries
Get CSL LTD SPON.ADR 2 Fundamental Data
CSL LTD SPON.ADR 2 Fundamental data includes:
- Net Revenue: 15 230 M
- EBITDA: 4 824 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSL LTD SPON.ADR 2 News
New
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alkermes (ALKS) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks pre...
Is There An Opportunity With CSL Limited's (ASX:CSL) 39% Undervaluation?
Key Insights The projected fair value for CSL is AU$391 based on 2 Stage Free Cash Flow to Equity Current share price of AU$239 suggests CSL is potentially 39% undervalued Analyst price target for CS...
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a l...
Life Sciences Investor Forum: Now Available for Online Viewing
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
